Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has shared an update.
CSL Limited announced a daily update on its ongoing on-market buy-back program, revealing the repurchase of 36,199 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 2,685,172. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, potentially impacting its market positioning and investor relations positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in the areas of immunology, hematology, and influenza vaccines, serving a global market.
Average Trading Volume: 1,168,335
Technical Sentiment Signal: Sell
Current Market Cap: A$90B
See more insights into CSL stock on TipRanks’ Stock Analysis page.